Chi Sheng Pharma & Biotech Co., Ltd.
TTPEX:411128.70
TWD
0.00
(0.00%)
ISIN
TW0004111000
Return %
Stock
S&P 500
1Y
-5.75
14.20
3Y
22.75
81.12
5Y
36.36
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Tung Mao Su
- Full Time Employees
- 80
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 3, Shih Chen Road Hsinchu Taiwan 30352
- IPO Date
- Mar 6, 1999
- Website
- cscp.com.tw
- Similar Companies
- Business
- Chi Sheng Pharma & Biotech Co., Ltd is a Taiwan-based pharmaceutical company principally engaged in the manufacture and distribution of medical medicines and equipment. The company offers a comprehensive portfolio of products including injections such as hemodialysis solutions, amino acid injections with electrolytes, vitamin injections, cephalosporin antibiotics, antihistamines, antipruritics, and ginkgo injections; oral solutions including antibiotics, cold syrups, and liquid antacids; externally applied medicines like contact lens solutions, normal saline wash, and povidone-iodine solutions; as well as consumptive products such as healthcare foods, skin care products, and cosmetics. It also provides medical devices and equipment. Chi Sheng Pharma & Biotech distributes its products domestically and internationally, with markets in Taiwan, Mainland China, and Southeast Asia. The company was originally founded as Chi Sheng Chemical Corporation in 1962 and rebranded to Chi Sheng Pharma & Biotech Co., Ltd to reflect its expanded focus on pharmaceutical and biotech segments. It holds ISO9001 and GMP food certifications, underscoring its adherence to quality standards. Chi Sheng maintains the largest market share in Taiwan for renal dialysate products, exceeding 50%. Recent operational highlights include continued expansion of its pharmaceutical product lines and strategic distribution growth into Southeast Asian markets, alongside ongoing development of parenteral-based medications. The company reported steady revenue growth in its pharmaceutical segment through to 2024 and remains active in medical innovation through collaborations within the biotechnology industry. Headquartered in Hsinchu Industrial Park, Taiwan, Chi Sheng Pharma & Biotech leverages its longstanding industry presence and robust manufacturing capabilities to serve healthcare providers and consumers. It targets medical institutions, pharmacies, and health-conscious consumers across its geographic footprint. The company's main operations emphasize injectable formulations, oral medicines, topical solutions, and healthcare consumables, positioning it as a key player in Taiwan's pharmaceutical and biotech sectors with expanding international reach. This description reflects Chi Sheng Pharma & Biotech's current product offerings, geographic markets, and recent strategic transformations within the last 1-2 years. The company continues to strengthen its market position by enhancing product innovation and broadening its service network while maintaining compliance with global standards.